Shares of BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) fell 3.8% during trading on Tuesday. The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares were traded during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Price Performance
The company has a market cap of C$168.68 million and a P/E ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 128.68 and a current ratio of 129.63. The firm’s fifty day moving average is C$10.60 and its two-hundred day moving average is C$10.60.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
See Also
- Five stocks we like better than BriaCell Therapeutics
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
